We serve Chemical Name:(Benzoylmethylene)triphenylphosphorane CAS:859-65-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:(Benzoylmethylene)triphenylphosphorane
CAS.NO:859-65-4
Synonyms:(Benzoylmethylene)triphenylphosphorane;EINECS 212-727-2;MFCD00014088
Molecular Formula:C26H21OP
Molecular Weight:380.41800
HS Code:
Physical and Chemical Properties:
Melting point:183-186°C
Boiling point:550.9ºC at 760 mmHg
Density:1.18g/cm3
Index of Refraction:1.646
PSA:26.88000
Exact Mass:380.13300
LogP:4.66560
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like (Benzoylmethylene)triphenylphosphorane chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,MFCD00014088 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,MFCD00014088 Use and application,EINECS 212-727-2 technical grade,usp/ep/jp grade.
Related News: ��Inceptua Medicines Access is delighted to be selected as Onconova��s partner for the Pre-approval Access Program for rigosertib. (Benzoylmethylene)triphenylphosphorane manufacturer In approving the first new Alzheimer’s drug in nearly 20 years, the U.S. Food and Drug Administration is taking its biggest risk yet with a strategy that allows new therapies onto the market without strong evidence that they work, regulatory and scientific experts say. (Benzoylmethylene)triphenylphosphorane supplier The government is leveraging its large patient population to push non-domestic drugs companies to cut prices to their lowest level globally. (Benzoylmethylene)triphenylphosphorane vendor The government is leveraging its large patient population to push non-domestic drugs companies to cut prices to their lowest level globally. (Benzoylmethylene)triphenylphosphorane factory Jo Soden, Co-managing Director of Retrogenix, said ��We look forward to working with Resonant to deconvolute the targets for their antibodies. Resonant��s innovative platform is delivering functional therapeutic candidates at rapid pace and we welcome the opportunity to identify the specific, biologically-relevant targets which will help progress these leads towards promising new therapies for patients with cancer.��
